Analysis
Crunchbase News published an analysis July 16 arguing that the recent wave of billion-dollar-plus rounds labeled "seed" in AI and biotech function much more like growth-stage capital deployments than traditional early-stage bets, despite carrying a label historically reserved for small, high-risk checks into unproven ideas.
The trend has been building for months -- Miles Wang's roughly $2 billion pre-launch talks for an AI-drug-discovery startup, reported earlier this month, is exactly the kind of round the analysis describes: pricing driven almost entirely by founder pedigree and technical-team quality rather than any demonstrated product, revenue or clinical validation, a pattern that would have been unthinkable for a seed-stage check even two years ago.
The shift concentrates capital in a small number of pedigreed founders emerging from frontier AI labs -- OpenAI, Anthropic, DeepMind -- and top biotech research institutions, at the expense of a broader base of less-pedigreed first-time founders who historically relied on smaller seed checks to prove out an idea before commanding growth-stage attention.
For emerging-manager and true early-stage funds, the analysis is a warning that the seed-stage ecosystem they were built to serve is bifurcating -- a small number of pedigree-driven mega-seeds are absorbing capital and attention that would once have supported a much broader base of smaller, genuinely higher-risk bets on unproven founders and ideas.
The bear case: pedigree-based pricing has produced real winners before -- several of today's largest AI labs were themselves priced heavily on founder reputation at inception -- so dismissing the pattern entirely risks missing genuinely differentiated teams. What to watch next: whether any of these billion-dollar "seed" rounds produce disclosed operating milestones within their first year that justify the label, or whether the pattern continues to drift the definition of seed-stage investing further from its historical meaning.
